<DOC>
	<DOCNO>NCT01906866</DOCNO>
	<brief_summary>The purpose study establish efficacy safety Circadin child neurodevelopmental disorder determine dose , randomize , placebo-controlled study plan evaluate efficacy double-blind , 13 week treatment period Circadin 2/5mg improve maintenance sleep , sleep latency additional parameter child neurodevelopmental disability . The efficacy safety Circadin 2/5 mg continue assess open-label extension period 13 week .</brief_summary>
	<brief_title>Efficacy Safety Circadin® Treatment Sleep Disturbances Children With Neurodevelopment Disabilities</brief_title>
	<detailed_description />
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Dyssomnias</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<criteria>To eligible study entry , patient must satisfy follow criterion screen : 1 . Must child 2 17.5 year age Visit 2 comply take study drug 2 . Must write informed consent provide legal guardian assent ( need ) 3 . Must document history ASD accord consistent ICD10 DSM5/4 criterion , neurodevelopmental disability cause neurogenetic disease ( i.e. , SmithMagenis syndrome , Angelman syndrome , Bourneville 's disease [ tuberous sclerosis ] ) confirm case note review show diagnosis reach assessment community pediatrician pediatric neurologist health care professional experience diagnosis take account early developmental history school record . 4 . Must current sleep problem include : minimum 3 month impaired sleep define ≤6 hour continuous sleep AND/OR ≥0.5 hour sleep latency light 3 5 night base parent report patient medical history . ( The maintenance latency problem necessarily 3 night week . ) 5 . May stable dose nonexcluded medication 3 month , include anti epileptic , antidepressant ( selective serotonin reuptake inhibitor [ SSRIs ] ) , stimulant , mood change drug βblockers . ( Only morning administration βblockers allow since βblockers night potential reduce endogenous melatonin level might cause disturbed sleep ) 6 . The sleep disturbance due direct physiological effect concomitant medication SSRIs , stimulant , etc . After complete 4 week sleep hygiene training ( need ) 2 week placebo runin , patient eligible continue study comply follow : Continue fulfill sleep problem criterion ( see Inclusion Criterion 4 ) base complete Sleep Nap Diary enter electronic case report form Parents demonstrate compliance Sleep Nap Diary completion ( 5 7 night ) . Compliance mean least 5 7 night per week ( total 2 week schedule visit ) parent complete diary page mandatory question Continue fulfil eligibility criterion Children meet follow criterion exclude participate study : 1 . Have treatment form melatonin within 2 week prior Visit 1 2 . Have know allergy melatonin lactose 3 . Have know moderate severe sleep apnea 4 . Have untreated medical/ineffectively treated/psychological condition may etiology sleep disturbance 5 . Did respond previous Circadin® therapy base past medical history record last 2 year 6 . Are take take prohibited medication within 2 week prior Visit 1 ( Section 7.1 ) 7 . Are females childbearing potential use contraceptive and/or breastfeed sexually active ( Abstinence acceptable method contraception . ) 8 . Pregnant females 9 . Are currently participate clinical trial participate clinical trial involve medicinal product within last 3 month prior study ( include patient participated Phase I PK study already include study ) 10 . Children known renal hepatic insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Sleep disturbance</keyword>
	<keyword>Circadian</keyword>
	<keyword>Prolong release melatonin</keyword>
	<keyword>Autism Spectrum Disorder</keyword>
	<keyword>Smith-Magenis Syndrome</keyword>
	<keyword>Angelman Syndrome</keyword>
	<keyword>tuberous sclerosis</keyword>
</DOC>